Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,515 | -5,506 | -14,084 | -12,582 | -11,341 |
| Depreciation Amortization | 2,174 | 2,130 | 263 | 194 | 124 |
| Accounts receivable | 12 | N/A | 342 | 284 | 283 |
| Other Working Capital | 217 | 707 | -29 | 21 | -280 |
| Other Operating Activity | 696 | 405 | 6,491 | 6,214 | 6,617 |
| Operating Cash Flow | $-6,416 | $-2,264 | $-7,017 | $-5,869 | $-4,597 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5 | -2 | -37 | -22 | N/A |
| Investing Cash Flow | $-5 | $-2 | $-37 | $-22 | $0 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 2,250 | 2,250 | 2,250 |
| Common Stock Issued | 10,506 | 9,561 | 4,959 | 4,959 | 4,933 |
| Other Financing Activity | -941 | -2 | 0 | 0 | 0 |
| Financing Cash Flow | $9,565 | $9,559 | $7,209 | $7,209 | $7,183 |
| Beginning Cash Position | 1,884 | 1,884 | 1,729 | 1,729 | 1,729 |
| End Cash Position | 5,028 | 9,177 | 1,884 | 3,047 | 4,315 |
| Net Cash Flow | $3,144 | $7,293 | $155 | $1,318 | $2,586 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,416 | -2,264 | -7,017 | -5,869 | -4,597 |
| Capital Expenditure | -5 | -2 | -37 | -22 | N/A |
| Free Cash Flow | -6,421 | -2,266 | -7,054 | -5,891 | -4,597 |